M

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Scientist 1/2 - Pre-Clinical Pharmacology

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeBoston, MA, USA$115k - $130kIn-person

About the Job

Requirements

  • A PhD in immunology, pharmacology, biology, or a related discipline with 0–6 years of post-doctoral academic and/or industry experience; or an MS with 5+ years; or a BS with 8+ years of relevant experience. An equivalent combination of education and experience will also be considered.
  • A strong foundational understanding of immunology, including innate and adaptive immune responses, immune cell subsets, cytokine biology, and interpretation of immune profiling data from preclinical studies.
  • Demonstrated experience designing and executing in vivo pharmacology studies in mice.
  • Strong expertise in flow cytometry, including panel design, instrument operation, data analysis, and interpretation.
  • Experience with blood and tissue processing, including immune cell isolation.
  • Experience with Western blotting, including automated platforms such as Jess.
  • Ability to manage multiple studies simultaneously with strong organization and attention to detail.
  • Ability and willingness to work onsite at least three days a week and flexible hours.

Responsibilities

  • Design, execute, and independently manage in vivo pharmacology studies supporting target validation, mechanism-of-action investigations, and efficacy assessment.
  • Serve as study lead for preclinical studies, coordinating activities across in vivo, biomarker, and discovery research teams.
  • Analyze, interpret, and present experimental results to project teams and leadership.
  • Identify experimental challenges, troubleshoot technical issues, and propose solutions.
  • Contribute to study planning, resource allocation, and prioritization of in vivo activities across multiple programs.
  • Perform and oversee complex in vivo studies in mouse models of inflammation, immunology, and oncology.
  • Perform animal procedures including compound administration by oral, intraperitoneal, and subcutaneous routes, blood collection, necropsy, and tissue harvest; intravenous administration is a plus.
  • Prepare and evaluate dosing formulations and support pharmacokinetic/pharmacodynamic studies.
  • Ensure study execution adheres to IACUC protocols, animal welfare standards, and company policies.
  • Participate in occasional evening and weekend study activities as required by experimental timelines.
  • Design, optimize, and execute multicolor flow cytometry experiments, including panel development, staining, acquisition, quality control, and data analysis.
  • Process and analyze blood and tissue samples for immune profiling and biomarker assessment.
  • Perform and interpret ex vivo and in vitro assays including cytokine analyses, ELISA/MSD, Western blotting, and related techniques.
  • Collaborate with cross-functional teams to develop and implement pharmacodynamic endpoints.
  • Provide scientific guidance and technical mentorship to Research Associates and junior scientists.
  • Help coordinate daily activities within the animal facility to ensure efficient study execution.
  • Maintain accurate experimental records, protocols, and study reports.
  • Contribute to development and implementation of standard operating procedures and best practices.
  • Support breeding colony management and other vivarium-related activities as needed.

Desired Qualifications

  • Experience in inflammatory disease, immunology, oncology, autoimmune disease research; cardiovascular disease research experience is a plus.
  • Experience with cytokine analysis platforms such as MSD and ELISA, and qPCR.
  • Ability to independently analyze data and communicate scientific findings effectively.
  • Experience with spectral flow cytometry and advanced analysis platforms such as FlowJo or similar.
  • Experience with mouse breeding colony management and genetically engineered mouse models.

About the Company

Monte Rosa Therapeutics

Develops targeted protein degraders for therapy

Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.

Company size
201-500
Company stage
IPO
Headquarters
Boston, MA
Founded
2018

Recently Posted Jobs

Explore more opportunities at Monte Rosa Therapeutics

See more jobs